See allLatest Trade Alerts

Brokerage Partners

Cramer's 'Mad Money' Recap: Look to Housing and Insurance

Written by: Scott Rutt 01/08/13 - 7:54 PM EST
Tickers in this article: AIG ANR BIIB EXC GLD HD IVR LL LOW NLY OC PFE PIR QCOR REGN SHW TRV VMC WHR WY
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Housing and insurance are two more themes that will be working in 2013, Jim Cramer told "Mad Money" viewers Tuesday in the next installment in his weeklong series on what investors should be buying on any Washington-induced market weakness.

Cramer said the housing market remains huge, and any company that sells into it should be yielding big returns in 2013. Of course that means the home builders, but they've already run a lot, said Cramer, which is why he'd look into the building-materials and home-furnishing companies.

Everything from Pier 1 Imports (PIR) to Owens Corning (OC) to Whirlpool (WHR) to Sherwin Williams (SHW) should be participating in the housing recovery, said Cramer.

More Headlines

That also means stocks like Weyerhaeuser (WY) , a stock Cramer owns for his charitable trust, Action Alerts PLUS, and Vulcan Materials (VMC) as well.

Cramer's next big theme for 2013: insurance. Yes, it's boring, he said, but given how beaten down this sector has been, there will be only upside as all of their beleaguered investments finally start bearing fruit. Cramer said he's a fan of Travellers (TRV) , along with American International Group (AIG) , another Action Alerts PLUS name.

Executive Decision

In the "Executive Decision" segment, Cramer spoke with Dr. Leonard Schleifer, president and CEO of Regeneron Pharmaceuticals (REGN) , one of the many companies presenting at the annual JPMorgan Chase (JPM) health-care conference this week.

Schleifer said Regeneron is celebrating its 25th anniversary this year and has always been based on doing good science that focuses on what patients need. That's why the company is working is many different areas from cholesterol to eye care.

When asked about the perceived weakness in the quarterly results, Schleifer said some analysts were expecting strong sales after a competitor ran into a formulation problem with a competing drug, but that scenario never materialized. He said Regeneron continues to grow at 50% a year and is expecting to have a phenomenal 2013.